Shuttle Pharma's Selective HDAC6 Inhibitor Shown To Stimulate Innate Immune Response In Pre-clinical Studies, As Reported In Molecular Cancer Therapeutics
Portfolio Pulse from Happy Mohamed
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) announced the publication of a manuscript reporting on the ability of its lead drug candidate (SP-2-225) to stimulate the immune system following radiation therapy. The study was supported by NIH grant and Cancer Research Institute Grant, and the drug was provided by Shuttle Pharmaceuticals under a material transfer agreement.
August 29, 2023 | 1:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Shuttle Pharmaceuticals' lead drug candidate (SP-2-225) has shown promising results in pre-clinical studies, potentially improving outcomes for cancer patients treated with radiation therapy.
The news of the successful pre-clinical studies of Shuttle Pharmaceuticals' lead drug candidate (SP-2-225) is likely to be viewed positively by investors. This could lead to increased investor confidence in the company and potentially drive up the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100